{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T07:49:17Z","timestamp":1791532157976,"version":"4.3.4"},"reference-count":48,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,10,9]],"date-time":"2027-10-09T00:00:00Z","timestamp":1823040000000},"content-version":"am","delay-in-days":373,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"NIH NIGMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jtct.2026.06.024","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:49:27Z","timestamp":1781801367000},"page":"1299.e1-1299.e15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating Day +90 Donor Chimerism as a Prognostic Marker of Clinical Outcomes Among Allogeneic Hematopoietic Cell Transplant Recipients Who Received Myeloablative Conditioning"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9546-4768","authenticated-orcid":false,"given":"Sara","family":"Jubas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8214-1591","authenticated-orcid":false,"given":"Kieran","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7143-1113","authenticated-orcid":false,"given":"Kendall","family":"Obara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1441-1814","authenticated-orcid":false,"given":"Hsuan-Hui (Grace)","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5468-7827","authenticated-orcid":false,"given":"Ryan M.","family":"Kemper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7712-2354","authenticated-orcid":false,"given":"Alexandra L.W.","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6942-8767","authenticated-orcid":false,"given":"Arushi","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0385-9219","authenticated-orcid":false,"given":"Tyler C.","family":"Dunlap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7234-9701","authenticated-orcid":false,"given":"Jing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8771-1191","authenticated-orcid":false,"given":"Riley M.","family":"Randolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9987-6613","authenticated-orcid":false,"given":"Jonathan R.","family":"Ptachcinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4486-0910","authenticated-orcid":false,"given":"Morgan E.","family":"Bizzell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3983-5534","authenticated-orcid":false,"given":"Paul M.","family":"Armistead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0145-6790","authenticated-orcid":false,"given":"Ryan","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8645-9469","authenticated-orcid":false,"given":"Anson E.","family":"Snow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3742-8863","authenticated-orcid":false,"given":"Daniel J.","family":"Crona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jtct.2026.06.024_bib0001","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/sj.bmt.1705582","article-title":"Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia","volume":"39","author":"Huisman","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2026.06.024_bib0002","first-page":"801","article-title":"Chimerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia","volume":"88","author":"Barrios","year":"2003","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.jtct.2026.06.024_bib0003","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1182\/blood.V87.7.3027.bloodjournal8773027","article-title":"Patterns of hematopoietic chimerism following bone marrow transplantation for childhood acute lymphoblastic leukemia from volunteer unrelated donors","volume":"87","author":"Molloy","year":"1996","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jtct.2026.06.024_bib0004","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.humimm.2021.07.013","article-title":"A practical guide to chimerism analysis: review of the literature and testing practices worldwide","volume":"82","author":"Blouin","year":"2021","journal-title":"Hum. Immunol"},{"issue":"2","key":"10.1016\/j.jtct.2026.06.024_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2024.11.006","article-title":"Early mixed donor chimerism is a strong negative prognostic indicator in allogeneic stem cell transplant for AML and MDS","volume":"31","author":"Radford","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"10.1016\/j.jtct.2026.06.024_bib0006","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.bbmt.2014.07.003","article-title":"Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning","volume":"20","author":"Reshef","year":"2014","journal-title":"Biol. Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.024_bib0007","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/tan.14557","article-title":"Utility of assessing CD3+ cell chimerism within the first months after allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia","volume":"100","author":"Bendjelloul","year":"2022","journal-title":"HLA"},{"issue":"10","key":"10.1016\/j.jtct.2026.06.024_bib0008","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.bbmt.2014.05.025","article-title":"Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival","volume":"20","author":"Koreth","year":"2014","journal-title":"Biol. Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.06.024_bib0009","article-title":"The predictive value of T-cell chimerism for disease relapse after allogeneic hematopoietic stem cell transplantation","volume":"15","author":"Li","year":"2024","journal-title":"Front. Immunol"},{"issue":"11","key":"10.1016\/j.jtct.2026.06.024_bib0010","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J. Clin. Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2026.06.024_bib0011","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41409-023-02139-5","article-title":"Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation","volume":"59","author":"Spyridonidis","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2026.06.024_bib0012","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.06.024_bib0013","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1182\/blood-2014-02-514778","article-title":"Conditioning regimens for hematopoietic cell transplantation: one size does not fit all","volume":"124","author":"Gyurkocza","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2026.06.024_bib0014","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.bbmt.2018.09.017","article-title":"Evaluation of a test dose strategy for pharmacokinetically-guided busulfan dosing for hematopoietic stem cell transplantation","volume":"25","author":"Davis","year":"2019","journal-title":"Biol. Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2026.06.024_bib0015","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.bbmt.2013.07.002","article-title":"Establishing a target exposure for once-daily intravenous busulfan given with fludarabine and thymoglobulin before allogeneic transplantation","volume":"19","author":"Russell","year":"2013","journal-title":"Biol. Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.024_bib0016","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1309\/QP7P-J49V-8Q15-36MT","article-title":"Evaluation of an automated technique for assessment of marrow engraftment after allogeneic bone marrow transplantation using a commercially available kit","volume":"113","author":"Nuckols","year":"2000","journal-title":"Am. J. Clin. Pathol"},{"issue":"4","key":"10.1016\/j.jtct.2026.06.024_bib0017","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L","article-title":"The use of the nitrogen mustards in the palliative treatment of carcinoma","volume":"1","author":"Karnofsky","year":"1948","journal-title":"Cancer"},{"issue":"29","key":"10.1016\/j.jtct.2026.06.024_bib0018","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO.2013.53.8157","article-title":"Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation","volume":"32","author":"Sorror","year":"2014","journal-title":"J. Clin. Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2026.06.024_bib0019","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood-2012-03-418202","article-title":"A disease risk index for patients undergoing allogeneic stem cell transplantation","volume":"120","author":"Armand","year":"2012","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.jtct.2026.06.024_bib0020","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.jtct.2026.06.024_bib0021","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1182\/bloodadvances.2024013275","article-title":"Association of busulfan exposure and outcomes after HCT for patients with an inborn error of immunity","volume":"8","author":"Bogn\u00e0r","year":"2024","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.jtct.2026.06.024_bib0022","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/sj.bmt.1704710","article-title":"CD34+ cell dose, conditioning regimen and prior chemotherapy: factors with significant impact on the early kinetics of donor chimerism after allogeneic hematopoietic cell transplantation","volume":"34","author":"Mohr","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"18","key":"10.1016\/j.jtct.2026.06.024_bib0023","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1182\/bloodadvances.2023009708","article-title":"Association between busulfan exposure and survival in patients undergoing a CD34+ selected stem cell transplantation","volume":"7","author":"Tamari","year":"2023","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jtct.2026.06.024_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193862","article-title":"Pharmacokinetics-adapted busulfan-based myeloablative conditioning before unrelated umbilical cord blood transplantation for myeloid malignancies in children","volume":"13","author":"Benadiba","year":"2018","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.jtct.2026.06.024_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2025.02.002","article-title":"Younger children with nonmalignant disease have increased incidence of mixed myeloid chimerism after allogeneic hematopoietic cell transplantation with busulfan-based conditioning","volume":"31","author":"Dvorak","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.jtct.2026.06.024_bib0026","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.42","article-title":"Systematic comparison of donor chimerism in peripheral blood and bone marrow after hematopoietic stem cell transplantation","volume":"7","author":"Bach","year":"2017","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.jtct.2026.06.024_bib0027","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41409-022-01579-9","article-title":"Chimerism analysis for clinicians: a review of the literature and worldwide practices","volume":"57","author":"Blouin","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.06.024_bib0028","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1600-0609.2005.00588.x","article-title":"Quantification of chimerism within peripheral blood, bone marrow and purified leukocyte subsets: comparison of singleplex and multiplex PCR amplification of short tandem repeat (STR) loci","volume":"76","author":"Beck","year":"2006","journal-title":"Eur J Haematol"},{"issue":"5","key":"10.1016\/j.jtct.2026.06.024_bib0029","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3390\/biomedicines14050952","article-title":"Lineage-specific chimerism analysis after allogeneic hematopoietic cell transplantation in patients with myeloid neoplasms: current evidence and considerations in the post-transplant cyclophosphamide setting","volume":"14","author":"Zaucha","year":"2026","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.jtct.2026.06.024_bib0030","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/bjh.14008","article-title":"Peripheral blood late mixed chimerism in leucocyte subpopulations following allogeneic stem cell transplantation for childhood malignancies: does it matter?","volume":"173","author":"Pichler","year":"2016","journal-title":"Br. J. Haematol"},{"issue":"11","key":"10.1016\/j.jtct.2026.06.024_bib0031","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/leu.2014.145","article-title":"Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis","volume":"28","author":"Stern","year":"2014","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.jtct.2026.06.024_bib0032","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.bbmt.2011.02.002","volume":"17","author":"Devine","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2026.06.024_bib0033","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/sj.bmt.1704281","article-title":"Should we T cell deplete sibling grafts for acute myeloid leukaemia in first remission?","volume":"32","author":"Chakrabarti","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"15","key":"10.1016\/j.jtct.2026.06.024_bib0034","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1200\/JCO.2005.09.117","article-title":"Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse","volume":"23","author":"Aversa","year":"2005","journal-title":"J. Clin. Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2026.06.024_bib0035","first-page":"1130","article-title":"Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia?","volume":"111","author":"Ringd\u00e9n","year":"2000","journal-title":"Br. J. Haematol"},{"issue":"24","key":"10.1016\/j.jtct.2026.06.024_bib0036","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1182\/blood-2013-08-519009","article-title":"Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation","volume":"122","author":"Bredeson","year":"2013","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2026.06.024_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2021.03.026","article-title":"Impact of total body irradiation-based myeloablative conditioning regimens in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: systematic review and meta-analysis","volume":"27","author":"Khimani","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"10.1016\/j.jtct.2026.06.024_bib0038","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/s41409-024-02413-0","article-title":"A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT)","volume":"59","author":"Domingos","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2026.06.024_bib0039","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/s41409-022-01641-6","article-title":"Impact of busulfan pharmacokinetics on outcome in adult patients receiving an allogeneic hematopoietic cell transplantation","volume":"57","author":"Seydoux","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2026.06.024_bib0040","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jtct.2021.04.007","volume":"27","author":"Kharfan-Dabaja","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.jtct.2026.06.024_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.03.025","article-title":"Peripheral blood CD34 donor chimerism has greater clinical utility than CD3 for detecting relapse after allogeneic stem cell transplantation for acute myeloid leukemia or myelodysplastic syndrome","volume":"29","author":"Das","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"10.1016\/j.jtct.2026.06.024_bib0042","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.bbmt.2014.05.026","article-title":"Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia","volume":"20","author":"Terwey","year":"2014","journal-title":"Biol. Blood Marrow Transplant"},{"issue":"14","key":"10.1016\/j.jtct.2026.06.024_bib0043","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1182\/bloodadvances.2022009493","article-title":"Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML\/MDS","volume":"7","author":"Loke","year":"2023","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.jtct.2026.06.024_bib0044","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jtct.2025.05.014","article-title":"Current activity trends and outcomes in hematopoietic cell transplantation and cellular therapy - a report from the CIBMTR","volume":"31","author":"Spellman","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"10.1016\/j.jtct.2026.06.024_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2025.05.006","article-title":"Comparison of chimerism kinetics and associated outcomes in patients receiving post-transplant cyclophosphamide versus methotrexate based GVHD prophylaxis following allogeneic hematopoietic cell transplant","volume":"31","author":"Baranwal","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1016\/j.jtct.2026.06.024_bib0046","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1182\/blood-2004-04-1506","article-title":"Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"104","author":"Baron","year":"2004","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2026.06.024_bib0047","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1182\/blood-2022-159411","article-title":"Reduced-intensity conditioning with fludarabine\/busulfan versus fludarabine\/low-dose melphalan in patients with non-hodgkin lymphoma undergoing allogeneic hematopoietic stem cell transplantation","volume":"140","author":"Kamijo","year":"2022","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2026.06.024_bib0048","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.bbmt.2016.04.026","article-title":"Fludarabine-busulfan reduced-intensity conditioning in comparison with fludarabine-melphalan is associated with increased relapse risk in spite of pharmacokinetic dosing","volume":"22","author":"Damlaj","year":"2016","journal-title":"Biol. Blood Marrow Transplant"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726004938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726004938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:56:33Z","timestamp":1791528993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726004938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2666636726004938"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.06.024","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating Day +90 Donor Chimerism as a Prognostic Marker of Clinical Outcomes Among Allogeneic Hematopoietic Cell Transplant Recipients Who Received Myeloablative Conditioning","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.06.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}